ImmunityBio, Inc. (IBRX)
ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion
ImmunityBio remains a long-term buy, with Anktiva's regulatory and global expansion driving the investment thesis. IBRX's EU commercial rollout via Accord Healthcare and new Dublin subsidiary rapidly expands Anktiva's addressable market and validates its global immunotherapy potential. The upcoming FDA decision on BCG-unresponsive papillary-only NMIBC is the next major catalyst, potentially multiplying Anktiva's eligible patient population.
Will Anktiva Continue to Drive ImmunityBio's Top-Line Growth in 2026?
ImmunityBio IBRX had an encouraging year in 2025. Last month, the company reported its fourth-quarter and full-year 2025 results, which beat both our earnings and sales estimates — all thanks to the strong financial performance of its sole marketed product, Anktiva.
IBRX and the BCG Shortage: A 2026 Catalyst Investors Are Tracking
ImmunityBio leverages a persistent BCG shortage and expanding Anktiva use in NMIBC, with 2026 catalysts including FDA talks, global launches and new clinical milestones.
IBRX Stock: Anktiva's Approvals and What Comes Next
ImmunityBio's Anktiva drives revenue surge and new approvals, as U.S. uptake and global launches set up a pivotal 2026.
ImmunityBio Valuation: Paying 33x Sales for Anktiva
IBRX stock surge has pushed valuation to ~33x sales as Anktiva adoption accelerates - but the premium assumes flawless commercialization and expansion.
ImmunityBio Stock Soars 295% YTD: Time to Buy, Hold or Sell?
IBRX stock surges nearly 300% YTD as Anktiva sales jump and global approvals expand, while premium valuation and single-drug reliance raise questions.
Why Is ImmunityBio Stock Soaring On Friday?
ImmunityBio Inc. (NASDAQ: IBRX) shares are up on Friday morning as the company completed its manufacturing engineering programs for its NK cell therapy platform.
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often take a niche approach, developing medicines aiming to address a specific type of cancer with particular dedicated mechanisms.
ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript
ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript
ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up
IBRX wins conditional EU approval for its Anktiva+BCG bladder cancer combo, sending shares soaring 41.9% and expanding its global footprint to 33 countries.
ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last?
ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
ImmunityBio: The Story Surrounding Anktiva So Far
ImmunityBio commands a premium valuation on the promise of Anktiva, a chemo-free immunotherapy platform showing early efficacy and manageable safety. IBRX's Anktiva is FDA-approved for BCG-unresponsive non-muscle invasive bladder cancer, with robust commercial traction—FY25 revenue reached ~$113 million, up 700% YoY. Key pipeline catalysts include upcoming trial readouts in bladder cancer and glioblastoma; positive data could drive further upside, but valuation is highly sensitive to setbacks.
